<DOC>
	<DOCNO>NCT01771458</DOCNO>
	<brief_summary>SHIVA proof concept randomize phase II trial compare two treatment strategy patient refractory cancer . From tumor biopsy , molecular profile disease establish ( mutation , amplification , hormone receptor status ) . If molecular abnormality identify approve targeted agent available , patient randomize randomized two arm : - Targeted therapy base molecular profile - Conventional therapy base investigator 's choice . A cross-over propose disease progression .</brief_summary>
	<brief_title>A Randomized Phase II Trial Comparing Therapy Based Tumor Molecular Profiling Versus Conventional Therapy Patients With Refractory Cancer</brief_title>
	<detailed_description />
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>1 . Patient recurrent/metastatic solid tumor fail candidate treatment usually propose first intention prospective clinical trial indicate tumor board 2 . ECOG performance status 0 1 3 . Biopsiable disease ( tumor biopsy mandatory tumor profile ) . The biopsy perform patient treated standard therapy recurrent/metastatic cancer plan treat molecularly target agent future . 4 . Measurable disease 5 . Adequate renal function define serum creatinine &lt; 1.5xUNL ( upper normal limit ) 6 . Adequate liver function test define SGOT &amp; SGPT &lt; 3xUNL ( 5xUNL case liver metastasis ) , bilirubin level &lt; 1.5xUNL 7 . Adequate bone marrow function define platelet &gt; 100,000/mm3 , hemoglobin &gt; 10 g/dL , neutrophils &gt; 1,000/mm3 8 . Patients must affiliate French Social Security System 9 . Signed informed consent 10 . For female childbearing potential : negative pregnancy test &lt; 72 hour start study treatment require . If sexually active , female childbearing potential must use `` highly effective '' method contraception study duration 3 month follow last treatment 11 . For male reproductive potential : sexually active male patient must use condom study treatment 3 month follow last treatment 12 . Agreement send CDROMs image central review 1 . Patients bone and/or brain metastasis 2 . Patients whose brain metastasis control &gt; 3 month 3 . Patient participate another clinical trial experimental drug 4 . Patients candidate receive molecularly target agent approve disease 5 . Anticoagulation antivitamin K ( Low Molecular Weight Heparin [ LMWH ] allow ) 6 . Patients concurrent severe and/or uncontrolled medical disease could compromise participation study , include uncontrolled diabetes , cardiac disease , uncontrolled hypertension , congestive cardiac failure , ventricular arrhythmia , active ischemic heart disease , myocardial infection within one year , chronic liver renal disease , active gastrointestinal tract ulceration , severely impaired lung function 7 . Pregnant and/or breastfeed woman 8 . Individually deprived liberty place authority tutor 9 . Patients psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule 10 . Known HIV , HBV , HCV infection Eligibility criterion randomize part : 1 . Identification tumor molecular abnormality Therapeutic Decision Committee ( TDC ) recommend molecularly target therapy available context trial ( even molecular profile incomplete ) 2 . Therapy recommend TDC approve patient 's disease 3 . ECOG performance status 0 1 4 . Adequate renal function define serum creatinine &lt; 1.5xUNL 5 . Adequate liver function test define SGOT &amp; SGPT &lt; 3xUNL ( 5xUNL case liver metastasis ) , bilirubin level &lt; 1.5xUNL 6 . Adequate bone marrow function define platelet &gt; 100,000/mm3 , hemoglobin &gt; 8 g/dL , neutrophils &gt; 1,000/mm3 7 . Albumin , LDH number metastatic site document ( order determine RMH prognostic score ) 8 . LVEF &gt; 50 % 9 . QTc &lt; 480 m ECG</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Metastatic/Reccurent</keyword>
	<keyword>Solid Tumor</keyword>
	<keyword>Refractory</keyword>
	<keyword>Molecular profile</keyword>
	<keyword>Targeted treatment</keyword>
</DOC>